XFOR X4 Pharmaceuticals Inc

X4 Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host a Conference Call and Webcast on August 8, 2024

X4 Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host a Conference Call and Webcast on August 8, 2024

BOSTON, July 30, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the second quarter ended June 30, 2024 and provide corporate updates on Thursday, August 8, 2024.

The company will host a conference call and webcast on the same day at 8:30 a.m. ET. The conference call can be accessed by dialing 1-800-225-9448 from the United States or 1-203-518-9708 internationally, followed by the conference ID: X4PHARMA. The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals’ website at . Following the completion of the call, a webcast replay will be available on the website.

About X4 Pharmaceuticals

X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has received U.S. approval as XOLREMDI™ (mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4 corporate headquarters are in Boston, Massachusetts and our research center of excellence is in Vienna, Austria. For more information, please visit our website at .

Company Contact:

José Juves

Head of Corporate & Patient Affairs

Investor Contact:

Daniel Ferry

Managing Director, LifeSci Advisors



(617) 430-7576



EN
30/07/2024

Underlying

XFORX4 Pharmaceuticals Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on X4 Pharmaceuticals Inc

 PRESS RELEASE
Free
XFOR X4 Pharmaceutic...

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Ru...

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on August 12, 2025, the company issued inducement awards to Adam Craig, M.D., John Volpone and David Kirske under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”), consisting of (i) options to purchase an aggregate of 4,250,718 shares of X4’s common stock granted to...

17h / 45m 1 EN
 PRESS RELEASE
Free
XFOR X4 Pharmaceutic...

X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Pl...

X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today closed an upsized private placement of 11,040,776 shares of common stock and pre-funded warrants to purchase 48,852,772 shares of common stock for total offering proceeds of $85 million. The originally announced offering of $60 million was increased to allow for the inclusion of an investor who had a pre-existing investment right. The offering was led by Coastl...

August 13, 2025 1 EN
 PRESS RELEASE
Free
XFOR X4 Pharmaceutic...

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurr...

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership $60 million PIPE financing led by Coastlands Capital, Bain Capital Life Sciences and New Enterprise Associates Newly appointed board and management team includes Dr. Adam Craig as Executive Chairman, John Volpone as President and David Kirske as Chief Financial Officer BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it has entered into a securities purc...

August 12, 2025 1 EN
 PRESS RELEASE
Free
XFOR X4 Pharmaceutic...

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial...

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA) Poster #1654 highlights clinically meaningful and durable increases in circulating neutrophils observed with mavorixafor treatment +/- G-CSF over 6-month study Poster #1669 highlights findings that investigators were willing and able to reduce injectable G-CSF while maintaining ANC levels in the normal range Data continue to strengthen confidence in potential success of ongoing global, pivotal Phase 3 trial evaluating ...

June 16, 2025 1 EN
 PRESS RELEASE
Free
XFOR X4 Pharmaceutic...

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for ...

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA BOSTON, June 10, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to mavorixafor, an oral CXCR4 antagonist, for the treatment of chronic neutropenia (CN). The company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in certain pr...

June 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch